search
Back to results

Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)

Primary Purpose

Cervical Cancer Screening

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Biop Colposcopy System
Sponsored by
BIOP Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Cervical Cancer Screening

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Females, ages 22 to 65 years old
  • Referred for colposcopy, following abnormal cervical cytology
  • Subject provides signed informed consent

Exclusion Criteria:

  • Currently pregnant or nursing
  • Currently menstruating
  • Currently has intrauterine device (IUD)
  • Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera.
  • Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system
  • HIV-positive status
  • Psychological instability, inappropriate attitude or motivation
  • Use of any additional experimental drug or device or participation in another clinical study within the past 30 days

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Biop Coplposcopy System

    Arm Description

    Biop Colposcopy system procedure

    Outcomes

    Primary Outcome Measures

    Performance
    The primary performance endpoint is the image registration success. Image registration success is defined by the registration error (distance between corresponding control points following registration). Average image registration error should be less than or equal to (≤) to 2mm.
    frequency and incidence of all Adverse Events
    Safety endpoints include frequency and incidence of all Adverse Events (AE) and Serious Adverse Events (SAE) related and unrelated to the device use.

    Secondary Outcome Measures

    Full Information

    First Posted
    November 14, 2018
    Last Updated
    January 14, 2020
    Sponsor
    BIOP Medical
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03750214
    Brief Title
    Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
    Official Title
    Bio Colposcopy System CIP: Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    May 2020 (Anticipated)
    Primary Completion Date
    November 2020 (Anticipated)
    Study Completion Date
    December 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    BIOP Medical

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.
    Detailed Description
    This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit. The Biop Digital Colposcope is intended for magnified viewing of the tissues of the vagina, cervix and external genitalia in order to assist doctors in diagnosing abnormalities such as lesions or cancer, and selecting areas for biopsy. The images from the digital colposcope are to be viewed on a color display. The digital colposcope is intended for use in hospitals, clinics, and doctor's offices. The Biop Micro Colposcope probe unit is an imaging tool intended to be placed in the vagina for acquisition of images of the cervix. It is intended as an adjunct to the Biop Digital Colposcope. It should NOT be used as a substitute for a thorough colposcopic evaluation. The Biop Micro Colposcope Probe unit is not intended for use on the vulva and vagina. It is anticipated that it will take approximately 3 months to complete active enrollment. Study duration for each subject is 1-2 days, including screening, enrolment and procedure. The study will be completed when the final study subject has completed the procedure. Performance - to confirm that average image registration error is less than or equal to (≤) 2mm. Safety - to evaluate the safety of the Biop Digital Colposcope in women undergoing cervical colposcopy procedures.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cervical Cancer Screening

    7. Study Design

    Primary Purpose
    Screening
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    26 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Biop Coplposcopy System
    Arm Type
    Experimental
    Arm Description
    Biop Colposcopy system procedure
    Intervention Type
    Device
    Intervention Name(s)
    Biop Colposcopy System
    Intervention Description
    The procedure stages: Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure. A questionnaire completed by the user after the Biop procedure, with regards to system usage Image Registration analysis
    Primary Outcome Measure Information:
    Title
    Performance
    Description
    The primary performance endpoint is the image registration success. Image registration success is defined by the registration error (distance between corresponding control points following registration). Average image registration error should be less than or equal to (≤) to 2mm.
    Time Frame
    procedure day ± 1 day
    Title
    frequency and incidence of all Adverse Events
    Description
    Safety endpoints include frequency and incidence of all Adverse Events (AE) and Serious Adverse Events (SAE) related and unrelated to the device use.
    Time Frame
    procedure day ± 1 day
    Other Pre-specified Outcome Measures:
    Title
    Exploratory Endpoint
    Description
    Subject's comfort - as measured by a questionnaire
    Time Frame
    procedure day ± 1 day

    10. Eligibility

    Sex
    Female
    Gender Based
    Yes
    Gender Eligibility Description
    Females, ages 22 to 65 years old
    Minimum Age & Unit of Time
    22 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Females, ages 22 to 65 years old Referred for colposcopy, following abnormal cervical cytology Subject provides signed informed consent Exclusion Criteria: Currently pregnant or nursing Currently menstruating Currently has intrauterine device (IUD) Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera. Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system HIV-positive status Psychological instability, inappropriate attitude or motivation Use of any additional experimental drug or device or participation in another clinical study within the past 30 days
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Dana Raveh Arbel
    Phone
    972528591891
    Email
    dana@biopmedical.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ram Eitan, Md.
    Organizational Affiliation
    RMC Israel
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)

    We'll reach out to this number within 24 hrs